Commitments and Contingencies - Additional Information (Detail) - USD ($)				1 Months Ended				3 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 05, 2019	Nov. 20, 2019	Apr. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2019	Jul. 01, 2018
Commitments And Contingencies [Line Items]
Renewal term of operating lease												1 year
Common stock issued to Microchips capital stock holders (in shares)									2,999,990
License fee									$ 533,334	$ 625,000
Defined contribution plan, employer matching contribution, percent of match									4.00%
Defined contribution plan, employer matching contributions									$ 96,000	$ 53,000
ADVA Tec Agreement | Minimum
Commitments And Contingencies [Line Items]
Percentage of royalty rate							1.00%
ADVA Tec Agreement | Maximum
Commitments And Contingencies [Line Items]
Percentage of royalty rate							10.00%
Juniper Pharmaceuticals, Inc.
Commitments And Contingencies [Line Items]
Upfront license fee paid				$ 250,000
Potential annual license maintenance fee, payments in year one				50,000
Potential annual license maintenance fee payments, thereafter				100,000
Juniper Pharmaceuticals, Inc. | Clinical And Regulatory Milestones
Commitments And Contingencies [Line Items]
Maximum potential milestone payments				13,500,000
Juniper Pharmaceuticals, Inc. | Sales Milestones
Commitments And Contingencies [Line Items]
Maximum potential milestone payments				$ 30,300,000
Upon Achievement Of Specified Development And Regulatory Milestones | ADVA Tec Agreement | Maximum
Commitments And Contingencies [Line Items]
Milestone payments								$ 14,600,000
Upon Reaching Certain Worldwide Net Sales Milestones | Licensing Agreements | ADVA Tec Agreement
Commitments And Contingencies [Line Items]
Milestone payments								$ 20,000,000
Microchips Biotech, Inc.
Commitments And Contingencies [Line Items]
Contingent consideration			$ 1,000,000								$ 1,000,000
Microchips Biotech, Inc. | Upon Achievement Of Specified Development And Regulatory Milestones
Commitments And Contingencies [Line Items]
Milestone payments			46,500,000
Contingent consideration			$ 55,000,000
SST | License And Collaboration Agreement
Commitments And Contingencies [Line Items]
Percentage of rights to inventions by employees under license agreement						50.00%
SST | License And Collaboration Agreement | Minimum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount						$ 500,000
SST | License And Collaboration Agreement | Maximum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount						18,000,000
SST | Upon Achieving Certain Commercial Milestones | License And Collaboration Agreement | Minimum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount						10,000,000
SST | Upon Achieving Certain Commercial Milestones | License And Collaboration Agreement | Maximum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount						$ 100,000,000
Orbis | Development And Option Agreement
Commitments And Contingencies [Line Items]
Milestone payments					$ 300,000
Commencement period for stage two upon achievement of stage one					90 days
Orbis | Upon Signing Of Development And Option Agreement | Development And Option Agreement
Commitments And Contingencies [Line Items]
Milestone payments					$ 150,000
Orbis | Upon Completion Of Fifty Percent Development Not Later Than Six Months | Development And Option Agreement
Commitments And Contingencies [Line Items]
Percentage of rights to inventions by employees under license agreement					50.00%
Milestone payments					$ 75,000
Orbis | Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months | Development And Option Agreement
Commitments And Contingencies [Line Items]
Milestone payments					$ 75,000
MilanaPharm | Licensing Agreements
Commitments And Contingencies [Line Items]
License Agreement Termination Periodic Discontinued Sale Of Product		60 days
License agreement, termination period due to performance failure		120 days
License agreement, notice period of termination		90 days
License fee		$ 25,000
License fee to be paid upon contingency		100,000
MilanaPharm | Upon Achieving Certain Commercial Milestones | Licensing Agreements | Maximum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount		1,750,000
MilanaPharm | Upon Achieving Certain Development Milestones | Licensing Agreements | Maximum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount		300,000
Hammock Pharmaceuticals, Inc. | Assignment Agreement
Commitments And Contingencies [Line Items]
License fee		250,000
License fee to be paid upon contingency		$ 125,000
Hammock Pharmaceuticals, Inc. | Upon Achieving Certain Clinical And Regulatory Development Milestones | Assignment Agreement | Maximum
Commitments And Contingencies [Line Items]
Milestone payments, contingent amount									$ 1,100,000
Common Stock | Microchips Biotech, Inc.
Commitments And Contingencies [Line Items]
Common stock issued to Microchips capital stock holders (in shares)			2,999,990
Subsequent Event | MilanaPharm | Licensing Agreements
Commitments And Contingencies [Line Items]
License fee to be paid upon contingency	$ 110,000
Subsequent Event | Hammock Pharmaceuticals, Inc. | Assignment Agreement
Commitments And Contingencies [Line Items]
License fee to be paid upon contingency	$ 138,000